Takeda wants to develop so-called digital biomarkers: data that gets collected whilst constantly monitoring patients with several devices. The company hopes that, by measuring activity levels, vital signs and sleep metrics, they will aid in the decision-making process off a patient. They also want to establish endpoints to be able to evaluate how a patient is functioning in day-to-day life. To achieve this the company collaborates with several different partners, who all focus on digital healthcare innovation.
Takeda has adopted the platform Koneska Health. This technological company works with data gathered through mobile, wearables and other digital devices. Koneska Health uses these to measure health indicators within their clinical trials. Takeda want to apply Koneska Health’s techniques to get a better understanding of novel technologies. It also enables the company to make their clinical trials more patient-centric. Takeda will use the sensors and devices Koneska Health provides.
The German company Definiens focuses on image- and data analysis. The company developed VeriTrova, a digital pathology platform to analyse biomarkers. VeriTrove makes it possible to share, view and analyse IHC images with different partners, from wet-lab partners to CRO’s. This makes it possible for the images to be analysed faster. Takeda is going to apply VeriTrova in another aspect of her clinical trials: tissue analysis. The new technology should make it possible to analyse the tissue in weeks, instead of months.
Takeda organised a competition during Health 2.0 in September to find digital health applications for people with multiple depressive disorder. The company is also working on a collaborative study with Vanderbilt University, where they research the usage of smartwatches for people with digestive health issues. This way, the 230 year old company is taking its first steps into the future of healthcare